Posted on

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers

Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers 

Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers

Go to Source

By sf-admin